NCT05219929View on ClinicalTrials.gov

Tetracycline Treatment Tolerability Trial

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Post-Treatment Lyme Disease
Interventions
DRUG

Tetracycline 500 Mg

500 mg three times daily

OTHER

Placebo

Placebo for Tetracycline given same way as Tetracycline.

Trial Locations (1)

21093

Johns Hopkins Lyme Disease Research Center, Lutherville

All Listed Sponsors
collaborator

Steve and Alexandra Cohen Foundation

UNKNOWN

lead

Johns Hopkins University

OTHER